openPR Logo
Press release

Direct synthesis of novel antivirals

12-13-2006 06:24 PM CET | Health & Medicine

Press release from: PharmaInformatic

Model of deactivated HIV-protease, an essential enzyme of HIV

Model of deactivated HIV-protease, an essential enzyme of HIV

Endotherm and PharmaInformatic announce their cooperation in developing and optimising drugs against infectious diseases

12. December 2006 (Saarbruecken/Emden, Germany) - Endotherm and PharmaInformatic today announced a collaboration to develop and optimise novel antiviral agents. PharmaInformatic, a company specialising in cheminformatics, will use it´s expert systems to predict antiviral and pharmacokinetic properties of novel compounds based on computer calculations. Promising drug candidates will be identified and directly synthesised by Endotherm.

The average cost of developing a new medicine is about 900 million US dollars and the whole process can take more than 12 years. A large part of research costs are spent on compounds that never make it to market because of insufficient ADME/Tox-properties. ADME/Tox stands for absorption, distribution, metabolism, excretion and toxicity.

ADME/Tox-properties are determined years after synthesis of an agent in clinical trials. The prediction of compound properties allows selection of those compounds with the best ADME/Tox-properties to become useful drugs, whereby efficiency of drug research is considerably increased early in the drug development process.

PharmaInformatic
Dr. Wolfgang Boomgaarden
Friesenstr. 36
Tel: +49 (0)4921-99 33 60
26721 Emden
Germany
Contact: http://www.pharmainformatic.com/html/contact_us.html

Endotherm GmbH
The company was founded in 1999 and provides exclusive synthesis of medicinally relevant compounds for the discovery and development of small molecule drugs. Endotherm’s customers include many of the world leading pharmaceutical companies, like Altana, Aventis, Bayer, Boehringer Ingelheim, Merck, Solvay, Schwarz Bioscience, Schering and Takeda. Further information: www.endotherm.de

PharmaInformatic
The company develops expert systems to optimise drug discovery and development. PharmaInformatic´s platform technology contains millions of substances together with experimental data and thousands of 3D-models of biomolecules. Proprietary methods based on cheminformatics and bioinformatics allow the prediction of pharmaceutical activity and pharmacological properties of a substance. Further information: www.pharmainformatic.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Direct synthesis of novel antivirals here

News-ID: 13679 • Views: 2229

More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral